In vivo antitumor activity by 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone in a solid human carcinoma xenograft model

Cancer Chemother Pharmacol. 2005 May;55(5):447-52. doi: 10.1007/s00280-004-0917-8. Epub 2005 Jan 22.

Abstract

Previously, we showed that 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone (DMC), isolated from the buds of Cleistocalyx operculatus, significantly inhibited the growth of human liver cancer SMMC-7721 cells and could induce SMMC-7721 cells apoptosis in vitro. Here, we report the antitumor effects of DMC in vivo, using a solid human tumor xenograft model with a human liver cancer SMMC-7721 cell line. Our results revealed that the average tumor weight in a control group and a 150-mg/kg DMC injection group was 1.42+/-0.11 g and 0.59+/-0.12 g, respectively. Flow cytometric analysis of the tumor cell population demonstrated the existence of an aneuploid peak (representing 33.60+/-0.80% of the total in the 150-mg/kg DMC injection group). To our knowledge, this is the first time that chalcone compounds were applied to a human tumor xenograft model.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor / drug effects
  • Chalcone / analogs & derivatives*
  • Chalcone / pharmacology
  • Chalcone / therapeutic use
  • Chalcone / toxicity*
  • Chalcones
  • Flow Cytometry
  • Humans
  • Liver Neoplasms / drug therapy*
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred ICR
  • Xenograft Model Antitumor Assays / methods*

Substances

  • Chalcones
  • Chalcone
  • angoletin